Abstract

BackgroundNaturally occurring Vif variants that are unable to inhibit the host restriction factor APOBEC3G (A3G) have been isolated from infected individuals. A3G can potentially induce G-to-A hypermutation in these viruses, and hypermutation could contribute to genetic variation in HIV-1 populations through recombination between hypermutant and wild-type genomes. Thus, hypermutation could contribute to the generation of immune escape and drug resistant variants, but the genetic contribution of hypermutation to the viral evolutionary potential is poorly understood. In addition, the mechanisms by which these viruses persist in the host despite the presence of A3G remain unknown.ResultsTo address these questions, we generated a replication-competent HIV-1 Vif mutant in which the A3G-binding residues of Vif, Y40RHHY44, were substituted with five alanines. As expected, the mutant was severely defective in an A3G-expressing T cell line and exhibited a significant delay in replication kinetics. Analysis of viral DNA showed the expected high level of G-to-A hypermutation; however, we found substantially reduced levels of G-to-A hypermutation in intracellular viral RNA (cRNA), and the levels of G-to-A mutations in virion RNA (vRNA) were even further reduced. The frequencies of hypermutation in DNA, cRNA, and vRNA were 0.73%, 0.12%, and 0.05% of the nucleotides sequenced, indicating a gradient of hypermutation. Additionally, genomes containing start codon mutations and early termination codons within gag were isolated from the vRNA.ConclusionThese results suggest that sublethal levels of hypermutation coupled with purifying selection at multiple steps during the early phase of viral replication lead to the packaging of largely unmutated genomes, providing a mechanism by which mutant Vif variants can persist in infected individuals. The persistence of genomes containing mutated gag genes despite this selection pressure indicates that dual infection and complementation can result in the packaging of hypermutated genomes which, through recombination with wild-type genomes, could increase viral genetic variation and contribute to evolution.

Highlights

  • Occurring viral infectivity factor (Vif) variants that are unable to inhibit the host restriction factor APOBEC3G (A3G) have been isolated from infected individuals

  • Virus containing the YRHHY > A5 mutation is inhibited in the presence of A3G and D128K-A3G but not A3F Our previous studies showed that a Vif mutant (YRHHY > A5), in which the Y40RHHY44 residues were substituted with five alanines, was unable to block the antiviral activity of A3G but was fully effective in blocking the antiviral activity of A3F [15]

  • To confirm that HIV-YRHHY > A5 showed the expected phenotype, the mutant and HIV wild type (WT) were first tested in a transient transfection system in the presence of A3G, A3F, and the D128K-A3G mutant which is resistant to human immunodeficiency virus type 1 (HIV-1) Vif-induced degradation [15,28,29,30,31]

Read more

Summary

Introduction

Occurring Vif variants that are unable to inhibit the host restriction factor APOBEC3G (A3G) have been isolated from infected individuals. Mulder et al have shown that a replication-competent virus containing mutations in Vif residues involved in interactions with A3G displayed reduced fitness in PBMC cultures; viral DNA in these cells contained extensive G-to-A hypermutation indicative of A3Ginduced cytidine deamination [14]. Among these viral clones drug-resistant variants existed that could be rescued through recombination with wild type (WT) HIV-1 following dual infection

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call